BR9505980A - Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso - Google Patents

Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso

Info

Publication number
BR9505980A
BR9505980A BR9505980A BR9505980A BR9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A BR 9505980 A BR9505980 A BR 9505980A
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
amino acid
production
pharmaceutical composition
acid sequences
Prior art date
Application number
BR9505980A
Other languages
English (en)
Other versions
BR9505980B1 (pt
Inventor
Francesc Mitjans
Jaume Piulats
Elisabet Rosell
Jaume Adan
Simon Goodman
Diane Hahn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9505980(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9505980A publication Critical patent/BR9505980A/pt
Publication of BR9505980B1 publication Critical patent/BR9505980B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI9505980-6A 1994-12-20 1995-12-20 fragmento de anticorpo monoclonal bivalente, bem como composiÇço farmacÊutica compreendendo o mesmo. BR9505980B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120165 1994-12-20

Publications (2)

Publication Number Publication Date
BR9505980A true BR9505980A (pt) 1997-12-23
BR9505980B1 BR9505980B1 (pt) 2010-02-23

Family

ID=8216547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9505980-6A BR9505980B1 (pt) 1994-12-20 1995-12-20 fragmento de anticorpo monoclonal bivalente, bem como composiÇço farmacÊutica compreendendo o mesmo.

Country Status (26)

Country Link
US (1) US5985278A (pt)
EP (1) EP0719859B1 (pt)
JP (1) JP3898245B2 (pt)
KR (1) KR100450368B1 (pt)
CN (1) CN1117763C (pt)
AR (1) AR001778A1 (pt)
AT (1) ATE244306T1 (pt)
AU (1) AU710234B2 (pt)
BR (1) BR9505980B1 (pt)
CA (1) CA2165573C (pt)
CO (1) CO4480042A1 (pt)
CZ (1) CZ290477B6 (pt)
DE (1) DE69531187T2 (pt)
DK (1) DK0719859T3 (pt)
ES (1) ES2202336T3 (pt)
FI (1) FI118536B (pt)
HU (1) HU221061B1 (pt)
NO (1) NO321186B1 (pt)
PL (1) PL182961B1 (pt)
PT (1) PT719859E (pt)
RU (1) RU2205223C2 (pt)
SI (1) SI0719859T1 (pt)
SK (1) SK284932B6 (pt)
TR (1) TR199501614A2 (pt)
UA (1) UA40621C2 (pt)
ZA (1) ZA9510806B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009651A1 (fr) * 1996-09-03 1998-03-12 Chugai Seiyaku Kabushiki Kaisha COMPLEXES D'ANTICORPS ANTI-INTEGRINE α3
EP0846702B1 (en) * 1996-12-09 2009-03-11 MERCK PATENT GmbH Soluble recombinant alphaV beta3 adhesion receptor
PT1930022E (pt) * 1997-08-08 2011-08-01 Univ California Tratamento da fibrose vesical com anticorpos contra integrina alfa-v-beta 6
CN1168741C (zh) * 1998-01-23 2004-09-29 默克专利股份有限公司 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US7153944B2 (en) * 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
US7064180B2 (en) 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
MXPA03007878A (es) * 2001-03-02 2004-07-08 Medimmune Inc Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
RU2316337C2 (ru) 2001-04-24 2008-02-10 Мерк Патент Гмбх КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2003006893A2 (en) 2001-07-09 2003-01-23 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
WO2003075741A2 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
CN100509851C (zh) * 2002-03-13 2009-07-08 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
NZ535425A (en) * 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
AU2004207002A1 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
KR20120035234A (ko) * 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
CA2646611A1 (en) 2006-03-21 2008-05-22 Genentech, Inc. Combinatorial therapy
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
HUE048024T2 (hu) 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
US20090196913A1 (en) * 2007-05-11 2009-08-06 Ken Shi Kun Huang Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
US20090175784A1 (en) * 2007-05-11 2009-07-09 Joshua Goldstein Anti-Alpha V Immunoliposome Composition, Methods, and Uses
EP2526967A1 (en) * 2007-07-17 2012-11-28 Merck Patent GmbH Engineered anti-alpha v-integrin hybrid antibodies
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
AU2009331955B2 (en) 2008-12-23 2015-09-24 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
US8124740B2 (en) 2009-03-25 2012-02-28 Genentech, Inc. Anti- α5 β1 antibodies and uses thereof
MX2012005423A (es) 2009-11-13 2012-06-14 Merck Patent Gmbh Anticuerpos anti-integrina unidos a nanoparticulas cargadas con agentes quimioterapeuticos.
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
WO2012027745A1 (en) * 2010-08-27 2012-03-01 University Of Miami Treatment of renal diseases
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
US20140127240A1 (en) 2011-04-21 2014-05-08 Bayer Pharma Aktiengesellschaft Novel Binder-Drug Conjugates (ADCs) and Use of Same
EP2744823B1 (en) * 2011-08-17 2017-08-02 The Regents of the University of California Antibodies that bind integrin alpha-v beta-8
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
PT3086814T (pt) 2013-12-23 2020-09-04 Bayer Pharma AG Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
RU2017113001A (ru) 2014-09-17 2018-10-17 Мерк Патент Гмбх Способ лечения метастазов в кости, предназначенные для этого медикаменты, и способ прогнозирования клинического исхода лечения метастазов в кости
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
EP3313523A2 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7034914B2 (ja) 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3510407A1 (en) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
KR101961715B1 (ko) 2018-07-18 2019-03-25 (주) 삼진정밀 고효율 수처리장치
CN113015747A (zh) 2018-10-19 2021-06-22 默克专利股份公司 用于治疗结肠直肠癌的阿比妥单抗
KR101999620B1 (ko) 2019-03-26 2019-07-12 조용진 부상슬러지 및 침전슬러지의 동시처리장치
JP2022527372A (ja) * 2019-04-08 2022-06-01 バイオジェン・エムエイ・インコーポレイテッド 抗インテグリン抗体及びそれらの使用
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578704A (en) * 1992-04-03 1996-11-26 Genentech, Inc. Antibody to osteoclast alphavbeta3 ntegrin
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis

Also Published As

Publication number Publication date
SK159295A3 (en) 1996-07-03
KR100450368B1 (ko) 2005-01-31
NO955167D0 (no) 1995-12-19
TR199501614A2 (tr) 1996-07-21
US5985278A (en) 1999-11-16
ES2202336T3 (es) 2004-04-01
FI956112A (fi) 1996-06-21
RU2205223C2 (ru) 2003-05-27
NO321186B1 (no) 2006-04-03
CO4480042A1 (es) 1997-07-09
ATE244306T1 (de) 2003-07-15
HUT74828A (en) 1997-02-28
EP0719859A1 (en) 1996-07-03
CA2165573A1 (en) 1996-06-21
AR001778A1 (es) 1997-12-10
BR9505980B1 (pt) 2010-02-23
ZA9510806B (en) 1996-05-30
SK284932B6 (sk) 2006-02-02
DK0719859T3 (da) 2003-10-20
PL182961B1 (pl) 2002-05-31
AU710234B2 (en) 1999-09-16
JP3898245B2 (ja) 2007-03-28
PL311926A1 (en) 1996-06-24
UA40621C2 (uk) 2001-08-15
JPH08231597A (ja) 1996-09-10
CZ328895A3 (en) 1996-09-11
KR960022562A (ko) 1996-07-18
AU4042195A (en) 1996-06-27
SI0719859T1 (en) 2003-12-31
FI118536B (fi) 2007-12-14
HU221061B1 (hu) 2002-07-29
DE69531187T2 (de) 2004-04-22
EP0719859B1 (en) 2003-07-02
CN1117763C (zh) 2003-08-13
PT719859E (pt) 2003-11-28
CA2165573C (en) 2011-03-29
HU9503638D0 (en) 1996-02-28
NO955167L (no) 1996-06-21
CN1139115A (zh) 1997-01-01
DE69531187D1 (de) 2003-08-07
CZ290477B6 (cs) 2002-07-17
FI956112A0 (fi) 1995-12-19

Similar Documents

Publication Publication Date Title
BR9505980A (pt) Anticorpo monoclonal seu fragmento linhagem de células de hibridoma sequências de aminoácidos e de DNA composição farmacêutica processo para a produção de um anticorpo monoclonal e seu uso
BR9606706A (pt) Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
BR8906988A (pt) Tetrapiptidio,peptidio,composicao farmaceutica,processo para uso de peptidio e reagente para diagnostico
DK0994728T3 (da) Rekombinante antistoffer, som er specifikke for beta-amyloide ender, DNA, der koder derfor, samt fremgangsmåder til anvendelse heraf
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
BR9401321A (pt) Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.
PT866876E (pt) Processo para a preparacao de proteinas recombinantes em e. coli por fermentacao a elevada densidade celular
BR9610180A (pt) Composição líquida autodepositante e processo para sua preparação
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
BR9505107A (pt) Composto composiçao farmacêutica processo para a preparaçao de um composto e seu uso
BR9004852A (pt) Composto,processo para sua preparacao,sua aplicacao e composicao farmaceutica
BR9610892A (pt) Processo para produzir produtos de polieteramina composto de polieteramina composição de combustível e aplicação de um composto de polieteramina
BR8905837A (pt) Composto,processo para sua preparacao e composicao fotocuravel
BR9601275A (pt) Compostos processo para sua preparação medicamentos preparação farmacêutica processo para sua produção e uso
BR9407874A (pt) Proteína purificada de mamiferos designada por mitosina fragmento biologicamente ativo proteina purificada de mamiferos molécula isolada de ácido nucléico vetor de expressao sistema de vetor-hospedeiro para produçao de mitosina anticorpo antimitosina e processo para produçao de mitosina
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
BR9508320A (pt) Processo para a preparação de um composto e cultura biologicamente
BR9200442A (pt) Anticorpo monoclonal,fragmento,celula de hibridoma,processos para a preparacao da celula e do anticorpo,processos para a purificacao e deteccao da presenca de sub-unidade alfa,processo para a determinacao da proporcao de ige,composicao,uso,celula e anticorpo
BR9602149A (pt) Compostos medicamento processo para manufatura e uso de esteres de ácido sulfúrico de açúcares amínicos
BR9709721A (pt) Polinucleotídeo purificado e isolado dna vetor célula hospedeira processo para prodzir quitanase humama para tratar uma infecção fúngica e para reduzir a quantidade de um ant-fúngico não-quitanase fragmento de polipeptídeo de quitanase humama linha de células de hiridoma anticorpo monoclonal e composição farmacéutica
DK0709455T3 (da) Monoklonalt antistof med humanglicentin, hybridoma til fremstilling af antistoffet og assaymetode for humanglicentin ved an
BR9603124A (pt) Dipeptídeo processo para preparação do mesmo mistura e medicamentos
BR9606521A (pt) Polinucleotídeo purificado e isolado molécula de dna construção de expressão de dna célula hospedeira método para produzir um polipeptídeo humano polipeptídeo purificado e isolado anticorpo e linhagem celular de hibridoma

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061586/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132267-10.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, MERIAL, MONSANTO TECHNOLAGY LLC.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: SOLICITADA ATRAVES DA PETICAO 860130005158, DE 21/10/2013

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061586/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL PROCESSO NO 2013.51.01.132267-0 AUTOR INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU(S): MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG, MERIAL E MONSANTO TECHNOLOGY LLC DECISAO: DIANTE DE TODO O EXPOSTO, HOMOLOGO OS ACORDOS RELATIVOS AS PI9505980-6, PI9603377-0 E PI9609387-0, PARA QUE SE PRODUZAM OS EFEITOS LEGAIS E DECLARO EXTINTO O PROCESSO, COM RESOLUCAO DO MERITO, NOS TERMOS DO ART 269, INCISO III, DO CODIGO DE PROCESSO CIVIL, COM RELACAO AS CORRES MONSANTO E MERCK PATENT GMBH.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 38/00 (2006.0

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.061586/2013-01 31A VARA FEDERAL DO RIO DE JANEIRO NUP: 00408.031526/2020-19 (REF. 0132267-10.2013.4.02.5101) AUTOR: INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL REU: MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG E OUTROS DECISAO: TRANSITO EM JULGADO EM 15.05.2020, DO ACORDAO FAVORAVEL AO INPI, QUE DEU PROVIMENTO A SUA APELACAO, EM PROCESSO QUE DISCUTE O PRAZO DE VALIDADE DAS PATENTES MAILBOX.